S10 - "Best Of" Session: MS and CNS Inflammatory Disease

Event Time: Monday April 24, 2017 8:00 am to 9:00 am
Topic(s): MS and CNS Inflammatory Disease
Description: A platform session that brings together the top four scoring abstracts in a particular topic, as rated by the topic reviewers. Offers an opportunity to interact with the author in a smaller setting at the conclusion of the session.
Completion Message:
CME Credits: 1
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
8:00 AM 001 Longitudinal characterization of cortical lesion evolution in multiple sclerosis by ultra high field MRI Constantina A Treaba
Dr. Treaba has nothing to disclose.

8:08 AM 002 Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study Douglas L Arnold, MD
Dr. Arnold has served on advisory boards, received speaker honoraria, served as a consultant for, or received research support from Bayer, Biogen, Coronado Biosciences, Consortium of Multiple Sclerosis Centers, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, Merck Serono, MS Forum, NeuroRx Research, Novartis, Opexa Therapeutics, Roche, S.A. Serono Symposia International Foundation, Teva, the Canadian Institutes of Health Research and Multiple Sclerosis Society of Canada.

8:16 AM 003 Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited. Shayandokht Taleb, MD
Dr. Taleb has nothing to disclose.

8:24 AM 004 Self-reported fatigue and lower limb problems predictive of conversion to secondary progressive multiple sclerosis in an aging sample of patients Caila Vaughn
Dr. Vaughn has nothing to disclose.

Ready to register for the 2018 AAN Annual Meeting?

Register Now

Related Courses